Jake Galson, Ph.D.Head of Technology at Alchemab Therapeutics
Dr. Galson is the Head of Technology at Alchemab Therapeutics. He oversees the development and usage of Alchemab's data-driven antibody and target discovery platform. Previously he was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Dr. Galson is one of the pioneers of immune receptor repertoire sequencing, serving as a member of the AIRR community, and authoring numerous publications in the area. He has worked at The Oxford Vaccine Group, GSK Vaccines, and University of Zürich, applying this approach to further understand basic immunology, as well as in support of vaccine development, diagnostics, and antibody drug discovery. Dr. Galson holds a BA in Biological Sciences and a PhD in Medical Sciences, both from the University of Oxford.